The "cash burn" is down to $221k (last quarter $542k).
I believe that a lot of the cash outflow this quarter was a once-of payment to SSI for the antigen license. If I am correct, then but for that CST would have been cashflow positive for the quarter.
Meantime, independant research (by me and others) is turning up new adopters of QuantiFERON around the world almost on a daily basis.
I am one happy little Gump.
I hope you are sitting on a tidy pile of this scrip, Alpha.
CST Price at posting:
0.0¢ Sentiment: None Disclosure: Held
